TFII.TO -1.7C 0.13MU -51.63CRWD 5.64PANW 6.15SNOW -4.82V -0.14MAL.TO -0.14
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.01
+0.10 (0.40%)
as of Jul 31, 2026, 8:00:00 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 2, 2026, 12:00 am

This summary was created by AI, based on 23 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing challenges following its pandemic-driven peak during which it surged due to COVID-19 vaccine sales. Experts have pointed out a lack of earnings momentum and concerns over a patent cliff, as key drugs have come off patent and the company needs to innovate to develop new blockbuster drugs. Despite these challenges, many analysts emphasize the attractive dividend yield, which remains around 6-8%. The company is pivoting towards growth areas such as obesity and oncology, and while there's a general belief that PFE is under pressure, patience from investors could yield positive results. Several insights indicate that while it may not attract immediate growth, the company’s efforts in acquisitions and drug development could eventually pay off, given time.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
DON'T BUY

Pfizer Inc(PFE)

Mar 28, 2002
Very expensive now. 8/10 X Book. Has some potential, but caution.
Photo of Ross HealyRoss HealyUnlock Rating
$39.74

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 15, 2002
Trading at high multiples.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. ScUnlock Rating
$41.37

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 12, 2002
A great long term hold for growth. Strong pipeline.
Photo of Mark Jackson, CFAMark Jackson, CFAUnlock Rating
$39.85

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 08, 2002
Prefers Glaxco Smith Klein.
Photo of David DriscollDavid DriscollUnlock Rating
$40.01

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 22, 2002
Prefers this and J&J over Merk. Will eventually give a 15/20% return.
Photo of Brad WillockBrad WillockUnlock Rating
$40.65

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 17, 2002
At a good price. Have a good drug pipeline. A premium company. Earnings growth should be 20% plus.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$40.13

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 11, 2002
(Was a top pick on June 14 down 5%) Has the best patent protection folio. Should grow 25% in 2002 and 15% for the next two years.
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$40.60

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 11, 2002
They have a good product line plus good new product development is excellent. Very cheap now.
Photo of Steven WipperstegSteven WipperstegUnlock Rating
$40.60

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 08, 2002
Good pipeline. Likes the price.
Photo of Jeff MorrisonJeff MorrisonUnlock Rating
$39.59

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 07, 2002
Likes the pharmaceutical sector. Has a good pipeline for its drugs.
Photo of Neil MurdockNeil MurdockUnlock Rating
$39.70

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 04, 2002
Likes the sector. Well positioned. Prefers over Merc.
Photo of John ZechnerJohn ZechnerUnlock Rating
$39.40

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 03, 2002
(Was a top pick on Sept 26 up 3.5%) Will have to buy some biotechs to keep their pipelines growing.
Photo of Joe ConnollyJoe ConnollyUnlock Rating
$39.70

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 02, 2002
(Was a top pick on Sept 10 up 4.4%) Not the best time to buy pharmaceuticals. Buy under $40.
Photo of Brad WillockBrad WillockUnlock Rating
$39.90

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 28, 2001
Very expensive. US drug companies are having problems.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$40.40

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 19, 2001
Good cash flow. Will grow 20% + 2002/03 and 15% 2004. A good price.
Photo of Michelle CalpinMichelle CalpinUnlock Rating
$41.10

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
Showing 826 to 840 of 885 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EOG 3.18$148.69
SLB 0.68$49.59
SHEL 1.47$91.98
AAPL -24.52$308.91
AMZN 36.08$271.58

Today's Top Picks

TFII.TO -1.7$13.38
C 0.13$132.45
MU -51.63$823.03
CRWD 5.64$190.86
PANW 6.15$331.83

Popular Articles

Latest Sell Signals

AAPL -24.52$308.91
AAPL -24.52$308.91
AAPL -24.52$308.91
T.TO -1.7$13.38
CCA.TO -1.1$59.1

Most Recent Experts

Amy Raskin, CIO, Chevy Chase Trust

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Brianne Gardner

Brianne Gardner

Raymond James

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like